Global Large Molecule Drug Substance CDMO Market Size study, By Services (Contract Manufacturing, Contract Development), By Source (Mammalian, Microbial, Others), By End-user (Biotech Companies, CRO, Others), and Regional Forecasts 2022-2028

Global Large Molecule Drug Substance CDMO Market Size study, By Services (Contract Manufacturing, Contract Development), By Source (Mammalian, Microbial, Others), By End-user (Biotech Companies, CRO, Others), and Regional Forecasts 2022-2028Global Large Molecule Drug Substance CDMO Market is valued at approximately USD 10.7 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 8.6% over the forecast period 2022-2028. Large-molecule drugs are known as biologics or biopharmaceuticals are sophisticated therapeutics that are thousands of times larger in molecular size compared to their chemically-synthesized counterparts. A contract development and manufacturing company (CDMO) is a company across the pharmaceutical sector that offers manufacturing services and drug development. Various pharmaceutical companies collaborate with CDMOs as a way to outsource drug development and drug manufacturing. The growing prevalence of various infectious diseases, surging demand for novel therapeutics, as well as rising number of strategic initiatives by the market players like investment, product launch, and many others are bolstering the market demand across the globe. For instance, in June 2020, FUJIFILM Corp. intended to invest nearly USD 778 billion for their FUJIFILM Diosynth Biotechnologies’ Denmark site, CDMO for advanced therapies and biologics. This investment supports Denmark's site’s existing drug substance manufacturing capability by double fold. Consequentially, growing initiatives by the market players are augmenting the market growth in the near future. However, several compliance issues are associated with outsourcing, and the imposition of regulatory and legal compliance impedes the growth of the market over the forecast period of 2022-2028. Also, the increasing research and development investments and growth of the biopharmaceutical sector are anticipated to act as catalyzing factors for the market demand during the forecast period.

The key regions considered for the global Large Molecule Drug Substance CDMO Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the heavy R&D investments, and the presence of various prominent market players. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as availability of a low-cost and skilled workforce as well as presence of favorable regulatory scenario would create lucrative growth prospects for the Large Molecule Drug Substance CDMO Market across the Asia-Pacific region.

Major market players included in this report are:

Eurofins Scientific
WuXi Biologics
Samsung Biologics
Catalent, Inc.
Cambrex Corp.
AGC Biologics
Recipharm AB (publ)
Siegfried Holding AG
LabCorp Drug Development
FUJIFILM Diosynth Biotechnologies

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Services:
Contract Manufacturing
Contract Development
By Source:
Mammalian
Microbial
Others
By End-user:
Biotech Companies
CRO
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Large Molecule Drug Substance CDMO Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors


Companies Mentioned

Eurofins Scientific
WuXi Biologics
Samsung Biologics
Catalent, Inc.
Cambrex Corp.
AGC Biologics
Recipharm AB (publ)
Siegfried Holding AG
LabCorp Drug Development
FUJIFILM Diosynth Biotechnologies

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.